Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
17 Ottobre 2022 - 12:00PM
Business Wire
Expands Coverage to Veterans Health
Administration and Military Health System Medical Centers for Its
Entire Lung Diagnostic Portfolio
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, today announced the
award of a U.S. Federal Supply Schedule contract which includes the
Veterans Health Administration providing care for U.S. Veterans and
Military Health System providing care for active-duty service
members and their families. The contract covers the company’s
entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®,
VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS™ testing. The U.S.
Department of Veterans Affairs (“VA”) is the largest integrated
health care system in the United States and provides care at 1,298
health care facilities, including 171 VA Medical Centers and 1,113
outpatient sites of care of varying complexity to over 9 million
veterans enrolled in the VA health care program.
“Partnering with the VA health system represents a large
opportunity for Biodesix to help improve care for Veterans by
integrating our five diagnostic tests into our country’s largest
health system,” said Scott Hutton, CEO of Biodesix. “An estimated
900,000 Veterans face an elevated risk and a 25% higher likelihood
of developing lung cancer compared to the general population. We
pride ourselves on being a patient-centric lung disease company,
focused on providing healthcare professionals with diagnostic tools
capable of transforming the standard of care and improving
outcomes. We are pleased to be aligning with the VA in this effort
to improve care for our Veterans.”
Lung cancer is the deadliest cancer worldwide and despite the
large number of treatments available to improve patient outcomes,
it remains an area of unmet needs. Biodesix offers healthcare
providers and patients a comprehensive suite of diagnostic tests
capable of supporting clinical decision-making across the lung
cancer continuum - from initial risk assessment of lung nodules
with the Nodify Lung® testing strategy, to post-cancer diagnosis
treatment guidance and monitoring with the IQLung™ testing
strategy. The Biodesix Nodify Lung testing strategy consists of two
blood-based proteomic tests, the Nodify CDT and Nodify XL2 tests,
designed to help healthcare professionals quickly and confidently
decipher the risk of malignancy of a lung nodule. The Company’s
IQLung Treatment Guidance testing consists of three blood-based
tests, the GeneStrat NGS and the GeneStrat ddPCR genomic tests, and
the VeriStrat proteomic test, which together provide a broader view
of each patient's disease state and empower healthcare
professionals with a testing strategy for any stage of non-small
cell lung cancer (NSCLC), delivering timely biological insights to
help expedite personalized treatment decisions.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The blood
based Nodify Lung® nodule risk assessment testing strategy,
consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in incidental pulmonary nodules, enabling
physicians to better triage patients to the most appropriate course
of action. The blood based IQLung™ strategy for lung cancer
patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™
test and the VeriStrat® test to support treatment decisions across
all stages of lung cancer with results in an unprecedented average
of 36-72 hours, expediting time to treatment. Biodesix also
leverages the proprietary and advanced Diagnostic Cortex® AI
(Artificial Intelligence) platform, to collaborate with many of the
world’s leading biotechnology and pharmaceutical companies to solve
complex diagnostic challenges in lung disease. For more information
about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221017005307/en/
Media: Kelly Mellott kelly.mellott@biodesix.com (773) 954
9752 Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Lug 2023 a Lug 2024